Automated 3D cell-based assays using a novel flowchip system and high-content imaging

Matthew Hammer, Carole Crittenden, Oksana Sirenko I Molecular Devices LLC Evan F Cromwell, Michelle Leung | Protein Fluidics, Inc.

### Introduction

There is an increasing interest in using three-dimensional (3D) cell structures for modeling tumors, organs, and tissue to accelerate translation research. Significant progress has been made in formation of such structures to recapitulate the *in vivo* environment but performing complex assays with them can be challenging. We present here results from automated organoid assays using a Pu·MA System coupled with high content imaging and fast fluorescence kinetic readouts. The flowchip contains organoid sample wells connected to multiple reservoirs that can contain various assay reagents. Organoids are located in protective chambers that allow media exchange, sample staining, wash steps, and other processing all to be performed without disruption to, or loss of 3D sample. The bottom of the sample chamber is thin optically clear plastic compatible with high resolution fluorescence imaging. We present two examples for disease modeling.

### **Oncology disease modeling**

- HeLa and HepG2 cells were dispensed 2,000-4000 cells per well (384-well ULA round bottom plate, Corning) and incubated for 72 hours until they formed tight spheroids<sup>2</sup>
- The spheroids and assay reagents were dispensed into to Pu-MA System flowchips and the processed as shown in Figure 2. Spheroids were treated with a serial dilution of staurosporine in triplicate. Staining was done after overnight incubation.
- Imaging was done with an ImageXpress Micro Confocal system and analysis performed using MetaXpress software. Customized analysis for multiparametric outputs was done using a protocol created in the MetaXpress Custom Module Editor. Results of imaging and analysis are shown in Figure 3.
- Conditioned media was recovered from wells, pooled together, and assayed for VEGF

## **Neurospheroid functional assays**

- Intracellular Ca<sup>2+</sup> oscillations can be used to observe neuronal "firing" in 3D neural cell cultures and assay effects of neuroactive compounds
- In this assay demonstration, neurospheroids (microBrain 3D, StemoniX) were preloaded into Pu·MA System flowchips, stained with FLIPR<sup>®</sup> Calcium 6 Assay Kit, and treated with compounds
- Ca<sup>2+</sup> oscillations were measured using the FLIPR<sup>®</sup> Penta High-Throughput Cellular Screening System. The flowchips and holder are compatible with the FLIPR optical system allowing quick measurements of the neurospheroids and returning to the incubator environment
- Assay workflow (Figure 5) provides complete media exchange and addition of increasing

- Assaying cytotoxicity effects of anti-cancer drugs on cancer spheroids
- Functional evaluation of calcium oscillations in neurospheroids

This novel assay method using microfluidics enables automation of 3D cell-based cultures that mimic *in vivo* conditions, performs multi-dosing protocols and multiple media exchanges, provides gentle and convenient handling of spheroids and organoids, and allows a wide range of assay detection modalities.

### **Pu·MA System assays**

Pu·MA System flowchips are designed with chambers and reservoirs arranged in a convenient multi-well plate format (384-well spacings) and provide up to 32 tests per plate. Once spheroids and reagents are loaded into the flowchips, the plate is placed into the Pu·MA System and reagent exchanges are done automatically through microfluidic channels connected to the protected sample chamber.

Multiple reagent exchanges are performed with assay protocols using built-in program. Assay protocols are preloaded into the system and run using an intuitive touchscreen interface. The whole Pu·MA System can be placed in an incubator to run assays at 37°C and 5% CO<sub>2</sub>. The system architecture and use of pneumatics to move fluids provides gas exchange to the sample chambers.



#### using a 96-well plate ELISA (Human VEGF DuoSet ELISA, R&D Systems)



Figure 2. Protocol steps for cancer spheroid assay. Spheroids were treated overnight with staurosporine. Staining reagents (1 μM calcein AM, 3 μM EthD-1, 33 μM Hoechst 33342) were added to flowchips after incubation period due to instability at 37°C. Plates with flowchips were removed from the Pu·MA System for downstream analysis.



#### concentrations of compounds to the same microtissue



Figure 5. Assay protocol workflow for neurospheroid function assay. Compounds are automatically transferred into the sample well. Flowchips are easily removed from the Pu·MA System for FLIPR Penta system measurements. Multiple compound treatments were done on the same neurospheroids.



Figure 1. Schematic of the automated organoid assay workflow coupled with high content 3D imaging.

### Instrumentation

The Pu·MA System and flowchips includes:

- Automated media exchanges occur with cells in protected chamber
- Supernatants can be collected to monitor cell secretion
- Cells can be lysed *in situ* for sensitive metabolomic profiling
- Spheroids can be imaged in the flowchip, or samples removed for immunoassay or metabolomics analysis

The ImageXpress<sup>®</sup> Micro Confocal High-Content Imaging System (IXM-C) includes:

- Four colors + transmitted light
- Environmental control
- Automated data analysis

The system is controlled by MetaXpress<sup>®</sup> High-Content Image Acquisition and Analysis Software





Figure 3. Quantitative assessment of the effect of staurosporine on spheroid morphology and viability by high-content imaging. Maximum projection images shown for HeLa (A) and HepG2 (B) control spheroids and spheroids treated with indicated increasing concentrations of staurosporine. HeLa cells were stained with Hoechst nuclear dye (blue), calcein AM viability dye (green) and EthD-1 dead cells dye (red). HepG2 cells were stained with Hoechst nuclear stain (blue), EthD-1 dye (red), NucView dye for apoptotic cells (green). C & D: Concentration-dependent plots shown below for percentages of live cell and dead cells quantitated in the images of spheroids for different concentrations of staurosporine. E: Concentration of VEGF measured in supernatants from HepG2 spheroids as a function of staurosporine concentration. Supernatants from two spheroids were combined and analyzed by ELISA for each measurement.

# **Microfluidic flowchip technology**

Each Pu·MA System flowchip contains eight lanes of reagent wells connected by microfluidic channels. Four flowchips are placed in holder that locates all wells in a 384-well plate format providing for 32 samples per assay. The compound wells in each lane hold media, compounds, or additional assay reagents. Organoids are placed into the sample well and located in a protected chamber at the bottom of the well. This allows reagents to be directed in and out of the sample well without disturbing or drying out the microtissue.



Figure 6. High-content imaging and recordings of Ca<sup>2+</sup> oscillations in neurospheroids. A: 2D Projection image of a neurospheroid stained with Hoechst (blue), calcein AM (green) and EthD-1 (red). B: Image of neurospheroid stained with Calcium 6 dye. C & D: Kinetic fluorescent recording or calcium oscillations measured by FLIPR Penta system. Recorded patterns were analyzed, and peaks counted by PeakPro2 software. Neurospheroids were stained with Calcium 6 dye and treated for 30 min with indicated compounds using the Pu·MA System. D: Concentration response of a single neurospheroid to 4-Aminopyridine. First measurement was with media only; 2nd with 1.1 μM 4-AP after 30 min incubation; 3rd with 10  $\mu$ M 4-AP after an additional 30 min incubation.

# **Conclusions**

- We have demonstrated capabilities of a novel automated 3D cell-based assay system that performs complex protocols with 3D cell models in an incubator environment.
- Cancer spheroid treatments were assayed using high resolution confocal imaging of

Figure 4. Schematic of flowchips showing channel layout and sample well with proprietary protected chamber. The diameter of the sample well clear aperture is 1.2 mm.

spheroids incubated with various compounds and live/dead staining and analysis. Automated neurospheroid treatments were performed with the Pu·MA System. Compatibility with the FLIPR Penta system allows multiple measurements of individual spheres with minimal time outside an incubator environment.

• The ability to analyze spheroids and organoids in situ in order to capture toxicity information and perform functional assays shows great promise for drug discovery.

For Research Use Only. Not for use in diagnostic procedures. ©2021 Molecular Devices, LLC. All Rights Reserved. The trademarks mentioned herein are the property of Molecular Devices, LLC or their respective owners. 2/21 2388A

